Zapater-Moros, Andrea
Díaz-Beltrán, Leticia
Gámez-Pozo, Angelo
Trilla-Fuertes, Lucía
Lumbreras-Herrera, María Isabel
López-Camacho, Elena
González-Olmedo, Carmen
Espinosa, Enrique
Zamora, Pilar
Sánchez-Rovira, Pedro
Fresno Vara, Juan Ángel
Funding for this research was provided by:
Consejería de Educación, Juventud y Deporte, Comunidad de Madrid (IND2018/BMD-9262, IND2018/BMD-9262)
Roche Farma (Roche Farma)
Fundación Bancaria Unicaja (ONCOCHJ-UNICAJA-P1)
Article History
Received: 24 February 2023
Accepted: 9 June 2023
First Online: 21 June 2023
Declarations
:
: JAFV, EE, and AG-P are shareholders in Biomedica Molecular Medicine SL. AZ-M and EL-C are employees of Biomedica Molecular Medicine SL.
: The study was approved by the Institutional Review Board of the Clinical Research Ethics Committee of Jaén (protocol code: PI-0455-2016 and date of approval: 27 October 2016). Clinical research was conducted under the Declaration of Helsinki and the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines. Written informed consent for participation was obtained from all patients involved in the study before blood sampling.